Monday 23 November 2026 The business of healthcare in India, the UK and the Gulf
The Healthcare Daily
Get The Handover

Pharma and life sciences

MHRA approves catumaxomab for malignant ascites through recognition route

The MHRA granted Atnahs Pharma UK a marketing authorisation for Korjuny on 2 October 2026. In the main study of 258 patients, time without further drainage was around 46 days against 11.

Follow on Google News (opens in a new tab)
Black and white photograph of glass medicine vials, ampoules and an intravenous fluid bottle
Representative photograph: medicine vials and an infusion bottle. National Cancer Institute on Unsplash.

What you need to know

  • The MHRA announced on 7 October 2026 that it had approved Korjuny (catumaxomab) for adults with malignant ascites when standard cancer treatment is no longer feasible.
  • The authorisation was granted to Atnahs Pharma UK Limited on 2 October through the International Recognition Procedure.
  • Price and NHS availability were not disclosed; the medicine was authorised in the EU in 2025 and launched in Germany by Pharmanovia that December.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Korjuny (catumaxomab) for adults with malignant ascites when standard treatment of their cancer is no longer feasible, the regulator announced on 7 October 2026. The marketing authorisation was granted to Atnahs Pharma UK Limited on 2 October through the MHRA’s International Recognition Procedure, according to the agency.

Malignant ascites is a build-up of fluid containing cancer cells in the abdomen, the MHRA said. Catumaxomab is a monoclonal antibody that binds to EpCAM, a protein found on certain cancer cells, and activates immune cells to help destroy them. It is given under the supervision of a doctor experienced in cancer treatment, as four infusions through a catheter into the abdominal cavity, with the dose increased at each infusion.

The MHRA announcement does not give a price, a UK launch date or any decision on NHS availability.

The evidence the MHRA cited

The MHRA said the main clinical study involved 258 patients with malignant ascites and EpCAM-positive cancer who had no further chemotherapy options or for whom chemotherapy was unsuitable. Patients treated with catumaxomab after paracentesis, the drainage procedure, did not need further drainage for around 46 days, compared with 11 days for those who had paracentesis alone, according to the regulator. The MHRA did not name the trial, the journal in which it was published, the publication date or the funder.

Side effects listed by the MHRA include nausea, vomiting, diarrhoea, abdominal pain, fever, chills, fatigue and cytokine release syndrome, an inflammatory reaction caused by immune activation. Julian Beach, the MHRA’s interim executive director of healthcare quality and access, said malignant ascites can place a considerable burden on people living with cancer, particularly when further treatment options are limited, described the approval as an additional treatment option that can help extend the time patients live without needing another procedure to drain fluid, and said the agency would monitor the medicine’s safety closely through the Yellow Card scheme.

A revived European asset

Korjuny already has a European commercial record. Lindis Biotech and Pharmanovia, a company that gives its address as Basildon, announced in February 2025 that the European Commission had granted marketing authorisation for catumaxomab, which had received a positive CHMP opinion under the brand name Korjuny, for malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for other systemic anticancer therapies. Under a licensing agreement, Lindis granted Pharmanovia exclusive rights to bring the medicine to market across Europe; financial terms were not disclosed. The same release said an earlier catumaxomab product, Removab, was first authorised in the EU in April 2009, had not been marketed since 2014 and was withdrawn from the EU in June 2017 for commercial reasons. Pharmanovia announced the launch of Korjuny in Germany in December 2025.

Neither the MHRA announcement nor the Pharmanovia releases read by The Healthcare Daily set out the commercial relationship between Pharmanovia and Atnahs Pharma UK Limited, the UK licence holder. The MHRA said the summary of product characteristics and patient information leaflet would be published on its products website within seven days of approval.

Our reading

Analysis by The Healthcare Daily.

  • The UK authorisation came through the International Recognition Procedure about 20 months after the European Commission approval announced in February 2025. Specialty companies holding European rights to niche oncology products can treat the UK as a follow-on market rather than a separate development programme.
  • For NHS commissioners, the figure that matters in the MHRA summary is time free of further drainage: around 46 days against 11 days in the main study. Whether that gain offsets the cost of repeat drainage procedures cannot be judged until a price is disclosed.
  • Hospital oncology services would need capacity for four escalating infusions given through an abdominal catheter, an operational question that will sit alongside any formulary decision.

Questions readers ask

What has the MHRA approved catumaxomab for?

The MHRA approved Korjuny (catumaxomab) for adults with malignant ascites when standard treatment of their cancer is no longer feasible. The authorisation was granted on 2 October 2026 and announced on 7 October.

Who holds the UK licence for Korjuny?

The MHRA named Atnahs Pharma UK Limited as the marketing authorisation holder. Pharmanovia holds exclusive European rights from the developer Lindis Biotech, according to a February 2025 release.

Is Korjuny available on the NHS?

The MHRA announcement does not say. No price or NHS availability decision was given in the documents The Healthcare Daily reviewed.

Sources

Announced plans, figures and dates are as stated in the sources below at the time of publication and can change. Conclusions drawn from them are our reading.

  1. MHRA: MHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen (7 October 2026)
  2. Pharmanovia: Lindis Biotech and Pharmanovia announce European marketing authorisation approval for catumaxomab (13 February 2025)
  3. Pharmanovia: Pharmanovia announces launch of Korjuny (catumaxomab) in Germany (15 December 2025)

Topics

The Healthcare Daily. We report from primary sources and list them on every story.

Read our editorial policy

The Handover

In a hospital, the handover is when one shift tells the next what changed and what to watch. Ours does the same for the business of healthcare, every weekday morning once it launches.

One email each weekday after launch. Unsubscribe at any time.

Search The Healthcare Daily

Saved stories

Kept in this browser only. There is no account and nothing is sent to us.